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Background: Progressive brain volume loss in schizophrenia has been reported in previous studies but its cause
and regional distribution remains unclear. We investigated progressive regional brain reductions in schizophre-
nia and correlations with potential mediators.
Method: Participants were drawn from the Northern Finland Birth Cohort 1966. A total of 33 schizophrenia indi-
viduals and 71 controls were MRI scanned at baseline (mean age = 34.7, SD = 0.77) and at follow-up (mean
age = 43.4, SD= 0.44). Regional brain change differences and associations with clinical mediators were exam-
ined using FSL voxelwise SIENA.
Results: Schizophrenia cases exhibited greater progressive brain reductions than controls, mainly in the frontal
and temporal lobes. The degree of periventricular brain volume reductionswere predicted by antipsychoticmed-
ication exposure at the fourth ventricular edge and by the number of days in hospital between the scans (a proxy
measure of relapse duration) at the thalamic ventricular border. Decline in social and occupational functioning
was associated with right supramarginal gyrus reduction.
Conclusion: Our ﬁndings are consistent with the possibility that antipsychotic medication exposure and time
spent in relapse partially explain progressive brain reductions in schizophrenia. However, residual confounding
could also account for the ﬁndings and caution must be applied before drawing causal inferences from associa-
tions demonstrated in observational studies of modest size. Less progressive brain volume loss in schizophrenia
may indicate better preserved social and occupational functions.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).ohort 1966; SIENA, Structural
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. This is an open access article under1. Introduction
Since the earliest neuroimaging studies using pneumoencephalo-
graphy, it has been postulated that there is progressive brain volume re-
duction in schizophrenia (e.g.Moore et al., 1935;Haug, 1962). However,
it was only with the application of modern neuroimaging techniques
and the introduction of control groups (Johnstone et al., 1976), and in
particular by the advent of longitudinal controlled MRI studies (DeLisi
et al., 1995; DeLisi et al, 1997), that progressive brain changes in schizo-
phrenia were conﬁrmed with greater certainty. Numerous MRI studiesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Demographic data.
Schizophrenia Controls
Mean SD N Mean SD N
Age at time point one (years) 34.12 0.63 33 34.97 0.67 71
Age at time point two (years) 43.21 0.43 43.52 0.41
Follow-up time (years) 9.10 0.59 8.54 0.66
Gender (men/women) 19/14 43/28
Handedness (right/left) 31/2 66/5
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progressive volume reductions in the frontal, temporal or parietal lobes
and/or progressive ventricular enlargement, compared to controls (e.g.
Saijo et al., 2001; Ho et al., 2003; Nakamura et al, 2007; van Haren et al.,
2007; DeLisi, 2008; van Haren et al., 2008; Andreasen et al., 2011; van
Haren et al., 2011; Cobia et al., 2012). The meta-analysis by Kempton
and colleagues (2010) pooled results from 13 studies examining ven-
tricular change in a total of 473 patients and 348 controls, ﬁnding that
patients show increased rates of ventricular enlargement over time
compared to controls. The meta-analysis by Olabi and colleagues
(2011) conﬁrmed evidence of progressive volume loss in frontal, tem-
poral and parietal regions, and of progressive ventricular enlargement,
compared to controls. However, two other meta-analyses present dif-
fering results. One meta-analysis that focussed on gray matter changes
conﬁrmed chronic temporal lobe progressive change but suggested a
nuanced picture with increased rates of widespread volume loss in the
earlier stages of illness (Vita et al., 2012). Ameta-analysis of progressive
change in a restricted set of regions in early-onset psychosis (mean age
of onset in the ﬁve included studies ranged between 13 and 16 years)
suggested that the frontal lobe was the only region in which brain
volume loss signiﬁcantly differed between patients and controls
(Fraguas et al., in press).
Given that there is signiﬁcant progressive brain structural change
during the course of schizophrenia, but not complete consensus even
amongst meta-analyses on the regional nature of change, further stud-
ies are required to explore the detailed regional basis of structural
changes. In order to evaluate the importance of morphological changes,
it is critical to examine whether the progressive changes are associated
with clinical and/or social function deterioration. Some groups have
suggested that greater brain atrophy over time predicts poor clinical
and social outcomes or greater brain reduction over time is correlated
with less improvement of clinical and social outcomes and/or duration
of time spent in hospital during the follow-up (e.g. DeLisi et al., 2004;
Andreasen et al., 2011; Asami et al., 2012). However, the associations
between regional brain structural change over time and clinical or social
outcomes in schizophrenia have not been universally replicated and it
remains uncertainwhich, if any, brain regions aremore vital than others
for long-term outcomes (van Haren et al., 2003; DeLisi, 2008; Olabi
et al., 2011; Gutiérrez-Galve et al., 2015).
Cumulative evidence has revealed signiﬁcant associations between
cortical and subcortical brain structural change and antipsychoticmedica-
tion exposure (e.g. Moncrieff and Leo, 2010; Ho et al., 2011; Ebdrup et al.,
2013; Haijma et al., 2013; Torres et al., 2013). The systematic review by
Fusar-Poli and colleagues (2013) reported that higher cumulative anti-
psychotic dose associatedwithmore pronounced decrease in graymatter
volume and increase in lateral ventricular size. In original studies, antipsy-
chotic medication exposure has been associated with, for example, de-
creases in frontal, temporal and parietal gray matter (Ho et al., 2011),
hippocampal volume (Ebdrup et al., 2011; Mamah et al., 2012) and tha-
lamic volume (Khorram et al., 2006), and increases in the volume of the
basal ganglia (Lang et al., 2004) and lateral ventricles (Crespo-Facorro
et al., 2008). However, this topic is controversial; furthermore, whether
typical and atypical antipsychotic medication have the same effects
on regional brain structure change in patients with schizophrenia re-
mains disputable (Ebdrup et al., 2013; Lieberman et al., 2005; McClure
et al., 2006; Navari and Dazzan, 2009; Smieskova et al., 2009).
We recently reported that antipsychotic medication exposure
predicted loss of total brain volume in schizophrenia over time (Veijola
et al, 2014) even after controlling for symptom severity, alcohol use and
weight gain; however, our recent study, like the majority of other papers
on this topic, looked only at summary brain volume indices rather than a
ﬁne-grained (voxel or vertex based) level of resolution. Indeed, only a
small number of voxel-based or vertex-based previous studies have ex-
amined progressive morphological change in schizophrenia at all, and
only one long-term study has examined associations betweenmedication
morphological change andmedication exposure at this level of resolution(vanHaren et al., 2011);moreover, as that study focussed only on the cor-
tex it could not address any association between medication exposure
and ventricular change. In this study, therefore, we employed voxelwise
analyses to examine progressive brain changes in schizophrenia com-
pared to controls, and the relationship between progressive changes
and symptoms, level of function and antipsychotic medication exposure.
2. Method
2.1. Participants
As described previously (Veijola et al, 2014), 33 patients with DSM-
III-R (Diagnostic and Statistical Manual of Mental Disorders Third
Edition Revised) schizophrenia and 71 controls, selected from a general
population-based birth cohort study, the Northern Finland Birth Cohort
1966 (NFBC 1966 www.oulu.ﬁ/nfbc), took part. Structured clinical in-
terview for DSM-III-R (SCID) and full case records were obtained and
scrutinized in order to validate the diagnoses using DSM-III-R criteria
(Isohanni et al., 1997; Moilanen et al., 2003). Table 1 shows the demo-
graphic characteristics of the ﬁnal 104 participants in the current
study. The mean age of patients with schizophrenia was 34.1 years at
baseline and 43.2 years at follow-up. The mean age of controls was
35.0 years at baseline and 43.5 years at follow-up (Table 1). There was
no signiﬁcant age difference between diagnostic groups. The patients
who took part in the study are representative of the entire popula-
tion of schizophrenia patients born in 1966 in Northern Finland in
terms of age, sex and educational level (Veijola et al, 2014). The av-
erage interscan interval signiﬁcantly (t (102) = 4.08, p b .000) dif-
fered between patients with schizophrenia (mean = 9.10 years,
SD = 0.59) and controls (mean = 8.54 years, SD = 0.66), hence
interscan interval, sex and handedness were used as covariates in
the group comparison statistical analyses. Permission to gather
data was obtained from the Ministry of Social and Health affairs,
and the study design was approved by the Ethical Committee of
the Ostrobothnian Hospital District, Oulu, Finland.
2.2. Clinical assessments
Clinical symptoms and social functioning in patients with schizo-
phrenia at baseline and follow-up were examined using three clinical
assessments: the Positive and Negative Syndrome Scale (PANSS), the
Clinical Global Impression (CGI) and the Social and Occupational Func-
tioning Assessment Scale (SOFAS) (Haapea et al., 2007; Veijola et al.,
2014). The change score of clinical assessments were calculated by
subtracting the scores of clinical assessments at follow-up from the
scores of clinical assessments at baseline. We also recorded time in hos-
pital during the interscan interval as a measure of illness severity in pa-
tients with schizophrenia, reasoning that hospitalization time was a
proxymeasure of relapse duration, which has been associated with vol-
ume loss in schizophrenia (Andreasen et al., 2011).
2.3. Antipsychotic medication exposure
Current and earlier use of antipsychotic medication was ascertained
by interview for all participants at both assessments, and individual
299J.Y. Guo et al. / Schizophrenia Research 168 (2015) 297–304hospital and outpatient case noteswere carefully reviewed to assess the
use of antipsychotic medication during the follow-up. During the
follow-up, three schizophrenia participants took no antipsychotic med-
ication and three took antipsychotic medication for less than one year.
We measured the use of antipsychotic medication in terms of chlor-
promazine equivalents and expressed the total use of antipsychotic
medication over the study period in terms of the number of dose
years of 100 mg of chlorpromazine daily (Veijola et al., 2014). Dose
years for total antipsychotic medication was used as a continuous vari-
able for our primary analysis and, as secondary analyses, we examined
dose years for typical and atypical antipsychotics separately.
2.4. The MRI scanner parameters
Brain MRI structural images from two time points in the present
longitudinal study were collected by a GE Sigma 1.5 Tesla MRI scanner
in Oulu University Hospital. See supplementary text for details of MRI
data acquisition.
2.5. Regional brain change calculations
Regional brain changes in all participants were calculated using
voxelwise SIENA (Structural Image Evaluation, UsingNormalisation) soft-
ware (Smith et al., 2002) in FSL (FMRIB software library) (Jenkinson et al.,
2012). Speciﬁcally, voxelwise SIENA normalizes the images of brain edge
displacements generated in SIENA, namely, ﬂow images, into MNI152
standard space for each participant. Then, the normalized ﬂow im-
ages of all participants are inputted into a non-parametric testing tool
(Randomise; Nichols and Holmes, 2002; Hayasaka and Nichols, 2003)
for statistical analyses. Notably, as voxelwise SIENA measures brain edge
displacements between two time points, the results of regional analyses
are purely restricted to the brain edge: SIENA differs in this respect from
classical voxel-based morphometry.
2.6. Statistical analysis
Voxelwise statistical analyses of the brain edge displacement
employed the permutation-based, voxelwise non-parametric test-
ing tool Randomise in FSL (Nichols and Holmes, 2002; Hayasaka
and Nichols, 2003). Randomise produced statistical images using the
threshold-free cluster enhancement (TFCE) function, thresholded at
p b 0.05 and corrected for multiple comparisons across the entire brain
edge using family-wise error correction. See supplementary material for
further details on statistical analyses.
3. Results
3.1. Regional brain structural change differences between patients with
schizophrenia and controls
In unadjustedmodels, schizophrenia patients displayed signiﬁcantly
(p b 0.05 family-wise error corrected across the brain edge) greater
regional brain reduction in widespread regions, including the bilateral
frontal pole, middle and inferior frontal gyrus, parietal lobes, bilateral
central gyrus, temporal lobes (including superior, middle and inferior
divisions), occipital lobes, precuneous, the right lingual gyrus (mid-line
occipital lobe), cerebellum and periventricular regions (supplementary
Table 1 and supplementary Fig. 1).
The results were similar when taking sex, handedness and interscan
interval (follow-up time) as covariates: schizophrenia patients exhibit-
ed signiﬁcantly greater regional brain reduction in the right frontal pole,
right middle and inferior frontal gyrus, bilateral central gyrus, bilateral
supramarginal gyrus, bilateral temporal lobe (including superior, mid-
dle and inferior divisions), right occipital cortex inferior division, right
lingual gyrus (mid-line occipital lobe) and bilateral precuneous cortex
(Table 2; Fig. 1). Global brain reduction was greater in patients withschizophrenia (mean = −6.13%, SD = 2.44) than controls
(mean=−4.07%, SD= 1.43). After taking into account the percentage
brain volume change (PBVC) global brain reduction (whether as a single
covariate or together with other covariates), no regions showed signiﬁ-
cantly greater reduction in schizophrenia compared to controls.
Unadjustedmodels did not document any regions in which controls
showed signiﬁcantly greater brain reductions than schizophrenia pa-
tients; however, after controlling for total percentage brain volume
change, sex, handedness and interscan interval (follow-up time), a sig-
niﬁcantly greater reduction in the right occipital pole was revealed in
controls than in schizophrenia patients, indicating relative sparing of
occipital lobe atrophy in patients (Table 3; supplementary Fig. 2).
3.2. Associations between regional brain structural changes and antipsy-
chotic medication exposure in patients with schizophrenia
3.2.1. Antipsychotic medication and brain reductions
Total antipsychotic medication exposure was signiﬁcantly (p b 0.05
family-wise error corrected across the brain edge) associated with
regional brain reductions in three clusters at the ventricular edge in pa-
tients with schizophrenia (please note that reduction in periventricular
brain volume in our analyses are equivalent to ventricular enlargement)
and in a cluster at the border of the substantia innominata (see Supple-
mentary Table 2 for peak voxel coordinates). The brain areas adjacent to
the areas of increased ventricular size included the bilateral lingual
gyrus, right thalamus, right caudate, bilateral callosal body, right cere-
bellum (bordering the fourth ventricle) and the brain stem (Fig. 2).
We extracted the mean brain edge movement for each of these four
clusters for each participant and ran further regression analyses to
determine if the associations were robust to co-varying for various po-
tential confounders.Whenwe adjusted for sex, interscan interval, hand-
edness, global brain volume change and severity of illness (by including
bothmean PANSS and interscan hospitalization time in themodels), the
associations between medication and brain reductions remained sig-
niﬁcant in the cluster at the cerebellar edge bordering the fourth ventri-
cle (unstandardized beta =−0.007, t=−3.34, p= 0.003) and in the
cluster at the edge of the substantia innominata (unstandardized
beta =−0.002, t=−2.53, p= 0.018).
Results of analyses examining the effects of typical and atypical
medications separately revealed a similar pattern of effects in the two
classes ofmedication; however, the effectswere stronger in atypicalmed-
ication analyses and only atypical medication exposure was signiﬁcantly
associated with brain reductions around the ventricles (Supplementary
Table 3 and Supplementary Fig. 3).
3.3. Associations between regional brain structural changes and clinical
assessments in patients with schizophrenia
3.3.1. Baseline clinical assessment scores and regional brain changes
None of the baseline clinical scores predicted regional brain structural
changes in patients with schizophrenia regardless of whether co-varying
for PBVC or not.
3.3.2. Hospitalization time and regional brain changes
The unadjusted model did not show any signiﬁcant association be-
tween regional brain atrophy and hospitalization duration. However,
therewas a signiﬁcant association between longer hospitalization dura-
tion (log10 days in hospital) during the interscan interval and ventricu-
lar enlargement at the thalamic border patients with schizophrenia,
while co-varying for sex, interscan interval and handedness (Supple-
mentary Table 4 and Supplementary Fig. 4). We extracted the mean
brain edgemovement for these clusters for each participant and ran fur-
ther regression analyses to determine if this association was robust to
co-varying for other potential confounders: global brain volume change,
mean PANSS and antipsychotic medication exposure. The association
between hospitalization time and brain reduction remained signiﬁcant
Table 2
Regions in which there were voxels showing greater volume loss in schizophrenia patients compared to controls (p b 0.05, FWE corrected, adjusted for sex, handedness and interscan
interval).
Regions Group Mean of Edge
Displacement
(mm)
Number of Voxels t p (peak) Coordinate of p Peak Voxel
(MNI152 mm)
Mean SD x y z
Right frontal pole Schizophrenia −0.42 0.29 694 4.20 .004 48 52 12
Control −0.21 0.17
Right middle frontal gyrus Schizophrenia −0.43 0.30 169 3.72 .006 56 34 18
Control −0.20 0.22
Right inferior frontal gyrus Schizophrenia −0.43 0.23 330 3.58 .004 64 6 2
Control −0.25 0.17
Bilateral central gyrus Schizophrenia −0.42 0.23 637 4.58 b .001 66 0 2
Control −0.22 0.14
Bilateral supramarginal gyrus Schizophrenia −0.35 0.26 607 5.65 b .001 −70 −44 −2
Control −0.14 0.15
Bilateral temporal lobe Schizophrenia −0.29 0.18 1726 5.67 b .001 −68 −46 −10
Control −0.11 0.10
Right occipital cortex (inferior division) Schizophrenia −0.28 0.23 182 3.57 .010 60 −70 2
Control −0.09 0.24
Right lingual gyrus (mid-line occipital) Schizophrenia −0.04 0.08 34 6.14 .011 8 −62 6
Control 0.05 0.07
Bilateral precuneous cortex Schizophrenia −0.13 0.10 95 4.68 .026 −4 −58 54
Control −0.04 0.05
Note: For reporting purposes, brain changes (p b 0.05 family-wise error corrected across the brain edge) were parcellated into regions using the Harvard–Oxford cortical structural atlas/
MNI structural atlas.
300 J.Y. Guo et al. / Schizophrenia Research 168 (2015) 297–304(unstandardized beta = −0.103, t = −2.40, p = 0.023) in the left
thalamic border cluster; the association in the right thalamic border
cluster was marginally signiﬁcant (unstandardized beta = −0.093,
t=−1.97, p= 0.059).
3.3.3. Clinical assessment score changes and regional brain changes
Improvement in SOFAS change score was signiﬁcantly associated
with less reduction of the right supramarginal gyrus over time in pa-
tients with schizophrenia, co-varying for sex, handedness andFig. 1. Brain edge regionswith greater loss of brain volume in schizophrenia patients compared
corrected across brain edge). Patients with schizophrenia showed signiﬁcantly greater regiona
frontal gyrus, bilateral central gyrus, bilateral supramarginal gyrus, bilateral temporal lobe (i
right lingual gyrus (mid-line occipital lobe) and bilateral precuneous cortex.interscan interval. The results remained signiﬁcant after also con-
trolling for total antipsychotic medication exposure or global brain
reduction as the extra covariate (Supplementary Table 5). In unad-
justed models, there was an association between frontal pole reduc-
tion and SOFAS decrease, but this was no longer signiﬁcant after
adjustment for sex, handedness and interscan interval. Neither CGI
change scores nor PANSS change scores predicted regional brain
structural changes in patients with schizophrenia regardless of co-
varying for PBVC or not.to controls (adjusted for sex, handedness and interscan interval, p b 0.05 family-wise error
l brain structural atrophy than controls in the right frontal pole, right middle and inferior
ncluding superior, middle and inferior divisions), right occipital cortex inferior division,
Table 3
Regions showing greater volume loss in controls compared to schizophrenia patients (p b 0.05 FWE corrected, adjusted for sex, handedness, interscan interval and percentage brain
volume change).
Clusters Group Mean of Edge
Displacement (mm)
Number of Voxels t p (peak) Coordinate of p Peak Voxel
(MNI152 mm)
Mean SD x y z
Right occipital pole Schizophrenia −0.28 0.57 105 4.38 .021 18 −102 −12
Control −0.42 0.48
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4.1. Regional brain structural change differences between schizophrenia
and controls
Patients with schizophrenia displayed greater signiﬁcant region-
al brain structural reduction than controls in widespread brain
regions in uncorrected analyses and when co-varying for sex, hand-
edness and interscan interval. The results suggested that schizo-
phrenia patients displayed excessive whole-brain reduction during
the course of schizophrenia, wherein the frontal, temporal and pari-
etal lobes exhibited non-signiﬁcantly greater reductions than other
brain regions, with relative sparing of the posterior occipital cortex.
The current results of the frontal, temporal and parietal lobe reduc-
tions in patients replicate and extend ﬁndings from meta-analysis
(Olabi et al., 2011; Vita et al., 2012). However, many previous results
have stemmed from results segmenting the brain at the lobar level,
whilst our results are more ﬁne-grained, extending to the voxel
level. Perhaps the most notable feature of our results is that even
using a ﬁne-grained voxel resolution technique, we document wide-
spread cortical and periventricular loss rather than any particularly
focal loss of brain volume; indeed after controlling for the overall
percent volume change, there are no regions that show signiﬁcantly
greater reduction in schizophrenia, emphasizing how widespread
the changes are.Fig. 2. Brain edge regions associated with total antipsychotic medication exposure over time
corrected across brain edge). More total antipsychotic medication exposure was signiﬁcantly a
of the substantia innominata, in schizophrenia patients.4.2. Relations between regional brain structural changes in patients with
schizophrenia and clinical measures
In line with some previous literature, neither clinical symptoms
nor social functioning at baseline predicted regional brain structural
progressive change in patients with schizophrenia (van Haren et al.,
2003). A positive result would have been expected if poor functioning
causes deterioration in brain volumes (for example, via inactivity).
However, the lack of association should not be interpreted as excluding
a causal relationship, given themodest sample size of the schizophrenia
group.
Change in social and occupational function was associated with re-
gional brain reductions in the right supramarginal gyrus (parietal
lobe) in patients with schizophrenia. This association remained signiﬁ-
cant after controlling for total antipsychotic medication exposure and
global brain reduction. This indicates that schizophrenia patients with
greater improvement, or less deterioration, of social and occupational
functions showed less regional brain reductions in the supramarginal
gyrus, independent from antipsychotic medication exposure. These re-
sults may relate to existing evidence that the supramarginal gyrus is in-
volved in neural circuits underlying the theory of mind (Fletcher et al.,
1995; Gallagher et al., 2000; Carr et al., 2003; Carrington and Bailey,
2009), which is impaired in schizophrenia (Horan et al., 2012; Fiszdon
et al., 2013) and is associated with social function in patients with
schizophrenia (McGlade et al., 2008; Couture et al., 2011).in patients with schizophrenia (uncorrected for any covariate, p b 0.05 family-wise error
ssociated with greater regional brain reductions around the ventricles, and at the border
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cupational function decline. Evidence for structural abnormalities of the
frontal pole in patients with schizophrenia have been reported in both
post-mortem (Benes et al., 1991) and MRI studies (Goldstein et al.,
1999; Rosso et al., 2010; Byun et al., 2012), with relationships to im-
paired executive functions (Orellana and Slachevsky, 2013) in schizo-
phrenia patients and social cognition (Bludau et al., 2014) in general.
As thisﬁnding did not remain signiﬁcant after adjustment for sex, hand-
edness and interscan interval, we are cautious in interpreting its signif-
icance. It should be noted that taking MRI and clinical measures at two
arbitrary timepoints and examining associations between their changes
is a crudemethodwithwhich to investigate relationships between biol-
ogy and course, as the clinical severity of schizophrenia may ﬂuctuate
markedly as the illness waxes and wanes,
We found an association between days spent in hospital and ventric-
ular enlargement around the thalamic border. This measure is a proxy
for time spent in relapse. As the association remained after controlling
for medication exposure and other potential confounders, this result is
in keeping with the result of the Suffolk County New York 10-year
follow-up study, which showed that total days in hospital was associat-
ed with left ventricular progressive enlargement between 5 and
10 years post-onset (DeLisi et al, 2004), and with the results of the
Iowa study that linked loss of brain volume to time spent in relapse, al-
though the location of their association was in the frontal lobe
(Andreasen et al., 2013). This result is consistent with the possibility
that time spent in psychotic relapsemay be causally related to brain vol-
ume loss, although causality cannot be inferred from an observational
study such as ours.
4.3. Antipsychotic medication exposure related regional brain structural
change in patients with schizophrenia
The present study showed that antipsychotic medication exposure
was associated with greater brain reduction around the ventricles (i.e.
ventricular enlargement) in patients with schizophrenia, independent
from illness severity and time in hospital. These results are consistent
with an early speculation by the neurologist Marsden (1976) and repli-
cate a milestone study with the largest sample size of patients with
schizophrenia (N = 211) so far and with a long follow-up period
(7.2 years on average compared to 9.1 years in our study) (Ho et al.,
2011). Although, a previousmeta-analysis failed to document an associ-
ation between antipsychotic medication exposure and progressive ven-
tricular enlargement in schizophrenia (Fusar-Poli et al., 2013), we note
that our study is theﬁrst long-term study to examine the association be-
tween ventricular or periventricular changes over time and medication
exposure at a voxel-level of resolution. Indeed our study is only the sec-
ond long-term study to examine the association between brain changes
andmedication exposure at the level of resolution of the voxel or vertex,
and the only previous study, by Van Haren and colleagues (van Haren
et al., 2011), examined only cortical thickness, and thus did not assess
the ventricles or periventricular regions.
There were nomarked differences in the effects of typical and atyp-
ical medications, although ourmodest sample size has limited power to
detect differential effects of different medications, and many patients
had taken different medications at different times before and during
the follow-up, making it hard to completely segregate the effects of dif-
ferent medications. We also noted a relationship between reduction at
the inferior edge of the substantia innominata andmedication exposure.
Other studies have suggested that associationmedication and brain vol-
ume reduction is likely to be more general (Ho et al., 2011; van Haren
et al., 2011; Fusar-Poli et al., 2013; Veijola et al., 2014). However, whilst
an advantage of a voxel-based study such as this is regional speciﬁcity,
the correction for multiple comparisons necessitated may result in
type II error; we were unable to document statistically robust regional
effects of medication that survived stringent correction for multiple
comparisons across other regions. We note that others have arguedthat the ventricular enlargement of schizophrenia patients in previous
studies is not directly associated with brain reductions in the adjacent
focal subcortical regions/white matter, but rather may indicate a (global)
graymatter decrease in schizophrenia patients (DeLisi et al., 2006; Horga
et al., 2011).
4.4. Strengths and limitations
A signiﬁcant strength of the current longitudinal study is our design
that ensured the same chronological age at baseline time for all partici-
pants, which reduces noise that could otherwise have been introduced
in the by non-linear ageing effects, and removes the necessity to control
for age in our study. Another advantage of the current studywas the use
of the FSL software tool SIENA,whichhas been argued to be themost ro-
bust software for estimating brain volume change over time and can
compensate for upgrades in MRI scanner hardware and software (de
Bresser et al., 2011). There were several limitations to be noticed in
the current study, which included an updated MRI scanner over the
follow-up; a modest sample size of patients with schizophrenia; differ-
ent criteria for PANSS scoring at two time points, and, as in nearly all ob-
servational medical studies, imperfect monitoring of medication
exposure during follow-up, although we painstakingly scrutinized hos-
pital records tominimisemeasurement error asmuch as possible. In fu-
ture work, the use of ingestible medication event markers or repeated
blood monitoring of drug levels would be an advantage although sus-
taining these procedures over several years will be challenging. Whilst
our study adds to evidence of association between antipsychotic medi-
cation exposure and brain morphological change, observational studies
such as this one cannot establish causality. In spite of our careful at-
tempts to control for various factors, it remains possible that the associ-
ations we observed could be secondary to residual confounding. A
common response by the clinician to a severely ill patient is to add
moremedicine: this is understandable under the commonmedical phi-
losophy that “more is better” (Malhotra et al., 2015). Severity may be
confounded with treatment dose in a way that makes it very hard (in
observational studies) to interpret whether any long-term brain chang-
es are ultimately related to medication or are secondary to a more se-
vere illness type, or some mixture of the two or to other potential
causal factors yet to be identiﬁed. In the future, observational studies
of the effects of antipsychotic (dopamine receptor antagonist) medica-
tion on brain structure in other disorders where their use is increasingly
common (e.g. Tourette’s syndrome, bipolar disorder, depression), and
additional controlled trials in patients with schizophrenia and in exper-
imental animals using brain structure as an outcomemeasure, will help
interpret the results of schizophrenia observational studies.
4.5. Conclusions
Our study documents excessive volume loss in schizophrenia com-
pared to controls in widespread regions. However, as volume loss had
few associations with clinical and functional outcomes, its signiﬁcance is
difﬁcult to judge. The ﬁndings of associations between progressive loss
of brain volume and antipsychotic medication, andwith time spent in re-
lapse, merit further study. The association between supramarginal gyrus
volume loss and decrease in social and occupational performance is not
secondary to medication, and emphasizes the importance of parietal
lobe structure in social function in schizophrenia.
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